Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

PUSHKAR M KANADE

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1144506445
CMS profile
879631
Location
CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$5,315.91

13 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Ardelyx, Inc. $4,500.00 4
Amgen Inc. $713.23 3
Travere Therapeutics, Inc. $50.36 3
Calliditas Therapeutics US Inc. $20.60 1
Fresenius USA Marketing, Inc. $16.98 1
ANI Pharmaceuticals, Inc. $14.74 1

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

PUSHKAR M KANADE

NPI 1144506445 · CMS profile ID 879631

Allopathic & Osteopathic Physicians / Internal Medicine

CLEVELAND, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1144506445?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1144506445?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1144506445?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
PUSHKAR M KANADE, NPI 1144506445, CMS profile ID 879631, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–13 of 13 matching records. This page contains 13 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1144506445?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

13 matching records · $5,315.91 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 13 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–13 of 13.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Calliditas Therapeutics US Inc. $20.6011/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234998925 CMS
Travere Therapeutics, Inc. $1.6611/12/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1244426619 CMS
Amgen Inc. $350.0010/24/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226897602 CMS
Ardelyx, Inc. $1,500.0010/22/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247857340 CMS
Travere Therapeutics, Inc. $24.6410/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244426623 CMS
ANI Pharmaceuticals, Inc. $14.7408/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1248613706 CMS
Amgen Inc. $350.0006/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1226923593 CMS
Travere Therapeutics, Inc. $24.0604/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244426621 CMS
Amgen Inc. $13.2302/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227075340 CMS
Ardelyx, Inc. $1,200.0002/11/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247857338 CMS
Ardelyx, Inc. $1,200.0002/04/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247857336 CMS
Fresenius USA Marketing, Inc. $16.9801/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244817051 CMS
Ardelyx, Inc. $600.0001/16/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1247857334 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2021 $278.46 6
PY2022 $209.73 11
PY2023 $10,131.26 35
PY2024 $15,559.15 44
PY2025 $5,315.91 13

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $362,982.61 42
PY2024 Principal investigator $25,154.84 14
PY2023 Principal investigator $41,380.36 45
PY2022 Principal investigator $127,066.20 120
PY2021 Principal investigator $6,314.90 3
PY2020 Principal investigator $80,106.36 12
PY2019 Principal investigator $78,304.52 13

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

120 records in PY2022

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $360.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272415
Principal investigator 1 CSL Behring $240.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272417
Principal investigator 1 CSL Behring $212.50 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272419
Principal investigator 1 CSL Behring $120.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272421
Principal investigator 1 CSL Behring $212.50 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272423
Principal investigator 1 CSL Behring $120.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272425
Principal investigator 1 CSL Behring $120.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272427
Principal investigator 1 CSL Behring $85.50 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272429
Principal investigator 1 CSL Behring $160.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272431
Principal investigator 1 CSL Behring $30.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272433
Principal investigator 1 CSL Behring $256.00 12/30/2022 Non-covered Recipient Entity
Great Plains Health Nephrology
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 950272435
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 12/19/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297573
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,662.50 12/19/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297575
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 12/19/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297577
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,662.50 12/19/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297579
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,250.00 11/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297563
Principal investigator 1 AKEBIA THERAPEUTICS INC $700.00 11/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297565
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 11/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297567
Principal investigator 1 AKEBIA THERAPEUTICS INC $700.00 11/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297569
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 11/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297571
Principal investigator 1 AKEBIA THERAPEUTICS INC $4,375.00 10/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297561
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,662.50 10/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297581
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 10/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297583
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,662.50 10/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297585
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 10/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297587
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297363
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297365
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297367
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297389
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297391
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297393
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,000.00 09/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297395
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297349
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297351
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297353
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297355
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297357
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297359
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,500.00 08/17/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297361
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297335
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,556.25 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297337
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297339
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297341
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297343
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297345
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 07/25/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297347
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297321
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297323
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297325
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297327
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297329
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297331
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,100.00 06/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297333
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297307
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297309
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297311
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297313
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297315
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,106.26 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297317
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 05/23/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297319
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297293
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297295
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297297
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297299
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297301
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297303
Principal investigator 1 AKEBIA THERAPEUTICS INC $500.00 04/20/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297305
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 03/23/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943767
Principal investigator 1 GlaxoSmithKline, LLC. $3,000.00 03/23/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943769
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297277
Principal investigator 1 AKEBIA THERAPEUTICS INC $587.50 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297279
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,387.50 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297281
Principal investigator 1 AKEBIA THERAPEUTICS INC $587.50 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297283
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297285
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,387.50 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297287
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297289
Principal investigator 1 AKEBIA THERAPEUTICS INC $2,200.00 03/22/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297291
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 03/18/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943759
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 03/18/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943765
Principal investigator 1 AKEBIA THERAPEUTICS INC $587.50 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297259
Principal investigator 1 AKEBIA THERAPEUTICS INC $587.50 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297261
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297263
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297265
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297267
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297269
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297271
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297273
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 02/18/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297275
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 02/11/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943763
Principal investigator 1 GlaxoSmithKline, LLC. $1,412.19 02/09/2022 Non-covered Recipient Entity
FRESENIUS MANAGEMENT SERVICES
A PHASE 3 RANDOMIZED, OPEN-LABEL (SPONSOR-BLIND), ACTIVE-CONTROLLED, P No dispute reported 06/30/2026 943943761
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,387.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297199
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297201
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,112.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297203
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297205
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,387.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297207
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,112.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297209
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297211
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297213
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,481.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297215
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,112.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297217
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,112.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297219
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297221
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297223
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,518.75 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297225
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297227
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297229
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297231
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,112.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297233
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297235
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297237
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297239
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,481.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297241
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,518.75 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297243
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,531.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297245
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,481.25 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297247
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,050.00 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297249
Principal investigator 1 AKEBIA THERAPEUTICS INC $1,387.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297251
Principal investigator 1 AKEBIA THERAPEUTICS INC $987.50 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297253
Principal investigator 1 AKEBIA THERAPEUTICS INC $293.75 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297255
Principal investigator 1 AKEBIA THERAPEUTICS INC $625.00 01/21/2022 Non-covered Recipient Entity
North Platte, Nebraska Hospital Corporation d/b/a Great Plains Health
A Randomized, Open-label, Active-controlled Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects No dispute reported 06/30/2026 885297257